236. 偽性副甲状腺機能低下症 Pseudohypoparathyroidism Clinical trials / Disease details
臨床試験数 : 3 / 薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 23
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04551170 (ClinicalTrials.gov) | July 13, 2020 | 9/9/2020 | Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1a | Drug: Theophylline;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 2 Years | 12 Years | All | 34 | Phase 2 | United States |
2 | NCT02463409 (ClinicalTrials.gov) | June 2015 | 20/5/2015 | Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) | Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a | Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline | Vanderbilt University Medical Center | Massachusetts General Hospital | Completed | 10 Years | 21 Years | All | 6 | Phase 2 | United States |